Tag: date

ZUG, Switzerland, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it has amended its loan facility (the “Amended Loan Agreement”) with funds and accounts managed by BlackRock (the “Lender”).

FORM 8.3

New York, NY, July 31, 2025 (GLOBE NEWSWIRE) -- The Ether Machine, the ether generation company, announced yesterday that The Ether Reserve LLC has purchased nearly 15,000 ETH at $3,809.97 USD for a total of $56,900,000.01 USD as part of The Ether Machine’s long-term accumulation strategy. This brings total ETH purchased and committed to 334,757 with up to $407,000,000 of USD remaining for additional ETH purchases.

STAMFORD, CT, July 31, 2025 (GLOBE NEWSWIRE) -- HCM III Acquisition Corp. (the “Company”), a blank check company whose business purpose is to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, announced today that it has priced its initial public offering of 22,000,000 units at $10.00 per unit. Each unit consists of one Class A ordinary share and one-third of one redeemable warrant. The units will be listed on the Nasdaq Global Market (“Nasdaq”) and will begin trading tomorrow, August, 1, 2025, under the ticker symbol “HCMAU." Each whole warrant is exercisable to purchase one Class A ordinary share of the Company at a price of $11.50 per share. Only whole warrants are exercisable and will trade. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the Nasdaq under the symbols “HCMA” and “HCMAW,” respectively.

Cayman Islands, July 31, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 152,106 of the Company’s ordinary shares originally issued in January 2025 at a reduced exercise price of $11.57 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-282932) and an effective resale registration statement on Form S-1 (No. 333-284873). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $1.8 million, prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about August 1, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes.

LA JOLLA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces a Standby Equity Purchase Agreement (SEPA) for up to $30 million worth of common stock over the course of 36 months.

VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), a licensed producer focused on cultivating and selling organic certified and premium cannabis, reports the voting results from its Annual General and Special Meeting of shareholders (the “Meeting”) held earlier today.

RUTLAND, Vt., July 31, 2025 (GLOBE NEWSWIRE) -- Casella Waste Systems, Inc. (“Casella”) (NASDAQ:CWST), a regional solid waste, recycling and resource management services company, today announced that it has priced the previously announced remarketing of $29.0 million aggregate principal amount of Finance Authority of Maine (the “Issuer”) Solid Waste Disposal Revenue Bonds (Casella Waste Systems, Inc. Project) Series 2015R-1 issued on August 27, 2015 and Series 2015R-2 issued on April 2, 2018 (collectively, the “Bonds”). The Bonds were originally issued in the aggregate principal amount of $30.0 million and have a final maturity of August 1, 2035. It is expected that $1.0 million of the aggregate principal amount of Bonds will be redeemed by Casella on August 1, 2025 with cash on hand, and the remaining $29.0 million of the aggregate principal amount of Bonds (the “Remarketed Bonds”) will be remarketed on such date. Pursuant to the indenture under which the Bonds were offered (the “Indenture”), the interest rate periods under which the Bonds were previously issued expire on July 31, 2025, and accordingly, the Bonds are subject to mandatory tender on August 1, 2025. Casella expects that the Bonds will be remarketed on August 1, 2025 at a new interest rate of 5.000% per annum for a new interest rate period commencing on August 1, 2025 and ending on July 31, 2035. The remarketing and redemption are expected to become effective on August 1, 2025, and the Remarketed Bonds are anticipated to be sold and designated as a single bond identified as Series 2015R-3.